Loading organizations...
Loading organizations...
Aegle Therapeutics: Clinical-stage biotech developing regenerative therapies using extracellular vesicles for rare skin disorders and severe burns.
Aegle Therapeutics is a clinical-stage biotechnology company developing regenerative therapies using extracellular vesicles secreted by mesenchymal stem cells, based in Miami, Florida. The firm utilizes intellectual property licensed from the University of Miami to create treatments targeting severe dermatological and immunological conditions, including rare genetic skin disorders like dystrophic epidermolysis bullosa and severe burns. Operating as a privately held enterprise with manufacturing facilities in Massachusetts, the company has secured over $40 million in total funding to advance its clinical trials. This capital includes a major Series A financing round backed by institutional investors such as New World Angels, Tellus BioVentures, and Defta Healthcare Technologies. The organization recently progressed its lead product candidate, AGLE-102, into Phase 1/2a clinical trials for the treatment of severe second-degree burns. Aegle Therapeutics was founded in 2013 by Dr. Evangelos Badiavas and Shelley Hartman.
Aegle Therapeutics has raised $6.5M across 1 funding round.
Aegle Therapeutics has raised $6.5M in total across 1 funding round.
Aegle Therapeutics has raised $6.5M in total across 1 funding round.
Aegle Therapeutics's investors include DeepWork Capital, Elona Baum, David Schimel, Lonnie Moulder.
Aegle Therapeutics has raised $6.5M across 1 funding round. Most recently, it raised $6.5M Series A in September 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 30, 2020 | $6.5M Series A | DeepWork Capital, Elona Baum, David Schimel, Lonnie Moulder |